Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCAustria - AuthorisedTherapeutic confirmatory (Phase III)
High Dose Steroids in Children with Stroke and Unilateral Focal Arteriopathy: A Multicentre Randomized Controlled Trial
This study looks at using strong steroid medicines to treat a type of stroke in children called focal cerebral arteriopathy (FCA). Researchers want to see if these medicines can reduce the inflammation in blood vessels and improve children's recovery.
Focal cerebral arteriopathy and childhood strokeFocal cerebral arteriopathy (FCA) is an inflammatory vessel wall diseaseprovoked by infection.Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
Sjögren’s SyndromeAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIb, Multicentre, Randomised, Double-Blind, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria
This study is looking at a new drug, balcinrenone, given with an existing drug, dapagliflozin (Forxiga), for people with long-term kidney disease and too much protein in their urine. It aims to see if this new combination helps protect the kidneys.
Chronic Kidney Disease and AlbuminuriaAustria - RecruitingPHASE2, PHASE3
Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide
This study looks at switching from one existing medicine, Bulevirtide, to a new one, Brelovitug, for people with long-term Hepatitis D. Researchers want to see if the new medicine is safe and works better.
Chronic Hepatitis DAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, single-arm, multicenter study to evaluate the efficacy and safety of caplacizumab and immunosuppressive therapy without first-line therapeutic plasma exchange in adults with immunemediated thrombotic thrombocytopenic purpura
This study is testing a new way to treat a rare blood disorder called TTP. It looks at whether a medicine called Cablivi, along with other treatments, can help people with TTP get better without needing a common but intensive procedure called plasma exchange.
Thrombotic Thrombocytopenic PurpuraAustria - Recruiting
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
This study looks at how a drug called elafibranor works for people with a rare liver disease called Primary Biliary Cholangitis (PBC) in everyday life. Researchers will check its effects, how safe it is, and how well people tolerate it over about five years.
Primary Biliary CholangitisAustria - Recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
This study looks at how well Medtronic heart devices, like pacemakers and defibrillators, perform over a long time. It helps ensure these devices are reliable and safe for people with heart conditions such as irregular heartbeats or heart failure.
ArrhythmiaBradycardiaHeart FailureSinus TachycardiaAustria - Active not recruitingPHASE3
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
This study looks at a new combination of medicines, enzalutamide and leuprolide, for men with prostate cancer that hasn't spread but is considered high-risk. The goal is to see how safe and effective this combination is in slowing down the cancer.
Hormone Sensitive Prostate CancerProstate CancerCancer of the ProstateAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
This study is testing a new medicine, secukinumab, for giant cell arteritis (GCA). It compares different doses of secukinumab with a dummy medicine (placebo), alongside a common steroid treatment. The aim is to see if secukinumab can help people with GCA stay well for longer.
Giant cell arteritis (GCA)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A phase 3b, prospective, open-label, multicenter, single treatment arm, continuation study of the safety and efficacy of TAK-755 (rADAMTS-13, also know as BAX930/SHP655) in the prophylactic and on-demand treatment of subjects with severe congenital thrombotic thrombocytopenic purpura (cTTP; Upshaw-Schulman Syndrome, or hereditary thrombotic thrombocytopenic purpura)
This study is looking at the long-term safety and helpfulness of a medicine called TAK-755 for people with a rare blood disorder called congenital TTP. It also checks how well TAK-755 prevents TTP episodes in those taking it regularly.
Congenital Thrombotic thrombocytopenic purpura (cTTP)Austria - RecruitingPHASE3
A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide
This study is for people with chronic Hepatitis D (HDV) whose current medicine, bulevirtide, isn't fully controlling the virus. It will test if a new combination of medicines, tobevibart and elebsiran, works better. It's a key step in finding more effective treatments.
Viral HepatitisAustria - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaAustria - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
This study investigates a new treatment, CAEL-101, for a serious heart condition called AL amyloidosis. Researchers want to see if CAEL-101 can help patients live longer and reduce hospital stays, alongside their usual medicine, compared to a dummy drug.
AL AmyloidosisAustria - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
Prostatic NeoplasmsAustria - RecruitingPHASE4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
This study looks at the best time to treat a rare twin pregnancy problem called TRAP sequence. We're comparing treating it early (12-14 weeks) versus later (16-19 weeks) to see which approach works better for the healthy twin. It's a randomised trial, meaning timing is decided by chance.
Twin Reversal Arterial Perfusion SyndromeAustria - Active not recruitingPHASE1, PHASE2
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
This study is looking into a new treatment, CC-99282, for non-Hodgkin lymphoma that has returned or not responded to other treatments. Researchers want to see how safe it is and how well it works, both by itself and with other lymphoma medicines.
Lymphoma, Non-HodgkinAustria - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A research study to evaluate the effects of single doses of NNC0614-0001 in healthy adult volunteers, and participants with hereditary haemochromatosis type 1.
This study is testing a new medicine, NNC0614-0001, on healthy adults and people with a blood condition called hereditary haemochromatosis type 1. Researchers want to see how a single dose affects the body, as this is the first time it's being given to people.
Hereditary haemochromatosis (HH) type 1Austria - RecruitingPHASE3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
This study looks at a new way to treat a specific type of leukaemia (AML) with a gene change called IDH1. It adds a drug called venetoclax to standard treatment (ivosidenib and azacitidine) to see if it works better. It's for patients who can't have strong chemotherapy.
Acute Myeloid LeukemiaAustria - Active not recruitingPHASE3
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
This study looks at a new drug, selumetinib, combined with standard chemotherapy (docetaxel) for a specific type of advanced lung cancer. It aims to see if this combination works better than chemotherapy alone for patients whose cancer has the KRAS gene mutation.
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IVAustria - RecruitingPHASE3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking into a new medication called Afimkibart for people aged 16-80 with ulcerative colitis that is moderately to severely active. It aims to see how well it works and if it's safe compared to a dummy drug. We hope it could be a new treatment option.
Moderately to Severely Active Ulcerative ColitisAustria - Active not recruitingPHASE3
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
This study looks at a new drug, erdafitinib, for advanced bladder cancer that has specific genetic changes. Researchers want to see if it works better than standard treatments like chemotherapy or pembrolizumab after previous treatments haven't helped enough.
Urothelial CancerAustria - RecruitingPhase III
A long-term extension (LTE) study of guselkumab in pediatric participants
This study looks at the long-term safety of a medicine called guselkumab for children and young people aged 2-17 with Crohn's disease, ulcerative colitis, or a type of arthritis called juvenile psoriatic arthritis. It's for those who have already benefited from guselkumab in a previous study.
Moderately to severely active ulcerative colitis (UC), moderately to severely active Crohn's disease (CD), Juvenile psoriatic arthritis (jPsA)Austria - RecruitingPHASE3
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
This study looks at a new medicine called ravulizumab for adults receiving a kidney transplant from a deceased donor. It aims to see if this medicine can help their new kidney start working well faster, reducing the need for dialysis after the operation.
Delayed Graft FunctionDGFKidney TransplantAustria - Active not recruiting
Go Fit Fast, Recovery Trajectory Using PROMIS®, Linking PROMIS®
This study looks at how people recover after breaking a bone like a hip or ankle. Doctors want to understand how things like walking patterns and pain levels change over time to help improve future treatments.
Hip FracturesTibial FracturesAnkle FracturesHumeral Fracture, ProximalAustria - Active not recruitingPHASE2
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
This study is looking at a new treatment called tabelecleucel for diseases linked to the Epstein-Barr virus (EBV). These can include certain cancers or conditions where the immune system isn't working properly. The study wants to see how well tabelecleucel works and if it's safe.
Epstein-Barr Virus (EBV)-Associated DiseasesEBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)Austria - Active not recruitingPHASE4
RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)
This study compares two treatments, Radium-223 (Xofigo) and ARPI therapy, for prostate cancer that has spread to the bones. It aims to see which is more effective and safer for men who have already tried ARPIs.
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Austria - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
Advanced Non-small Cell Lung Cancer, HER2 MutationAustria - RecruitingPhase III
Astria STAR-0215-302 trial for Navenibart in Hereditary Angioedema
This study looks at a new medicine called navenibart for hereditary angioedema (HAE). It aims to see how safe it is and how well people tolerate it over a long time. Navenibart might help prevent HAE attacks, which can be severe and painful.
Hereditary angioedemaAustria - Active not recruitingPHASE3
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
This study is testing a new medicine, Tinengotinib, for people with a type of bile duct cancer called cholangiocarcinoma. It's for those whose cancer has specific genetic changes (FGFR-altered) and hasn't responded to previous treatments, including an FGFR inhibitor drug. Researchers want to see if Tinengotinib is safe and works better than other treatments.
CholangiocarcinomaAustria - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
This study looks at a new drug, INCA33890, alongside standard treatments for advanced bowel cancer that has spread. It aims to see if adding INCA33890 helps people live longer and keeps the cancer from growing for a longer time.
Metastatic Microsatellite Stable Colorectal CancerAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
This study is testing a new drug, pemigatinib, against standard chemotherapy for a type of bile duct cancer (cholangiocarcinoma) that has spread or can't be removed, and has a specific gene change. It wants to see which treatment works better and is safer as a first treatment.
CholangiocarcinomaAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough
This study looks at a new medicine called BI 1839100. It's for people with lung conditions like Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF) who have a troublesome cough. We want to see if the medicine can reduce coughing and if it's safe to use.
Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)Austria - RecruitingPHASE3
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
This study is looking at new drug combinations for people recently diagnosed with a type of blood cancer called multiple myeloma. It compares two new treatments, Teclistamab or Talquetamab, each given with standard drugs, against the usual standard treatment, to see which works best.
Multiple MyelomaAustria - RecruitingPHASE2
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
This study looks at a new drug, trastuzumab deruxtecan (T-DXd), for advanced breast cancer that has specific features. It compares this drug to standard treatments to see if it helps patients live longer without their cancer getting worse.
Advanced Breast CancerAdvanced Breast CarcinomaHormone Receptor Positive Breast CarcinomaAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Neovascular Age-related Macular Degeneration (wet AMD)Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety and tolerability of different doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF).
This study is testing a new medicine, BI 1819479, for idiopathic pulmonary fibrosis (IPF). We want to see if it can slow down the lung scarring and if it's safe. Some people will get the medicine, others a dummy pill. We'll check how your breathing changes over about a year.
idiopathic pulmonary fibrosisAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
CABONEN – a phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3
This study is testing a new medicine, cabozantinib, for people with a type of advanced neuroendocrine cancer. Doctors want to see how well it controls the cancer and if it improves quality of life. It's a phase II trial, meaning it's still in early stages of testing.
Neuroendocrine NeoplasiaNeuroendocrine TumorAustria - Active not recruitingNA
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
This study looks at whether closing off a small part of the heart called the left atrial appendage (LAA) during heart surgery can help prevent strokes in people at risk. They're comparing it to standard care in those having heart operations.
Ischemic StrokeSystemic EmbolismAustria - RecruitingPHASE3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
This study is looking at a new drug, Saruparib, for men with high-risk prostate cancer and a faulty BRCA gene. It aims to see if adding Saruparib to standard treatments can help prevent the cancer from spreading.
Prostate CancerAustria - Active not recruitingPHASE3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.
Metastatic Castration-resistant Prostate CancerAustria - Enrolling by invitation
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
This study is checking on people who've had special cell treatments for cancer in previous Kite studies. We want to see how these treatments affect their health and well-being over a long time, looking at safety and how well they continue to work.
Solid and Hematological MalignanciesAustria - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A research study comparing different ways of increasing the dose of NNC0519-0130 in participants with overweight or obesity
This study is looking for volunteers to test a new way of giving a medicine called NNC0519-0130. It's for people who are overweight or have obesity and Type 2 diabetes. The aim is to find the best and safest dose.
Type 2 diabetes mellitusAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks in patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
This study is testing a new medicine, BI 1015550, for people with progressive fibrosing interstitial lung diseases (PF-ILDs). Researchers want to see if it helps improve lung function and is safe to use over about a year.
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Austria - Active not recruitingPHASE3
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
This study looks at a new medicine called ravulizumab for people with kidney disease having heart surgery. It aims to see if the medicine can prevent serious kidney problems after the operation. It's for adults aged 18-90.
Chronic Kidney DiseaseCKDCardiac DiseaseCardiopulmonary BypassAustria - RecruitingPHASE3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
This study looks at a new way to treat a common eye condition called wet Age-related Macular Degeneration (AMD). It tests a small, refillable implant that delivers medicine directly to the eye, hoping to reduce how often people need eye injections.
Neovascular Age-related Macular DegenerationAustria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response
This study looks at new treatments for a type of blood cancer called Chronic Myeloid Leukaemia (CML). It compares a new drug, asciminib (Scemblix), with existing treatments (imatinib or nilotinib) in people whose CML hasn't fully responded to imatinib yet. The main goal is to see which treatment helps more people achieve a very low level of cancer cells.
Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular responseAustria - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesAustria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients
This study is looking at a new medicine, sotatercept, for people recently diagnosed with a serious lung condition called Pulmonary Arterial Hypertension (PAH). It compares sotatercept to a dummy medicine to see if it improves well-being and reduces serious health events when added to standard treatments.
Therapeutic confirmatory (phase III)Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2- negative Breast Cancer (OlympiaN)
This study is looking at new ways to treat a specific type of early breast cancer in people with a gene change called a BRCA mutation. It tests two medicines, olaparib alone and olaparib with durvalumab, to see how well they shrink tumours before surgery and if they are safe.
BRCA Mutations and Early Stage HER2-Negative Breast CancerAustria